Elicio 10-Q: Q3 Loss Narrows to $8.0M, Going Concern Reiterated, Cash to Q2 2027
ELTX is trading near its 52-week low of $1.4 (0.4% above the low).
Summary
Elicio's Q3 2026 10-Q shows a narrower $8.0 million quarterly loss and $30.9 million of cash, but management still flags substantial doubt about going concern with runway only into Q2 2027 after raising about $42 million of equity in nine months.
Key Events · Earnings and Guidance · ELTX
-
Q3 Loss Narrows to $8.0M
Net loss for Q3 2026 was $7.979 million, or $0.30 per share, versus $10.083 million, or $0.60 per share, in Q3 2025; the nine-month loss was $28.019 million versus $31.853 million.
-
Going Concern Doubt Reiterated
The 10-Q states that losses, negative operating cash flows and the capital needed for the next twelve months raise substantial doubt about the ability to continue as a going concern.
-
Cash of $30.9M, Runway to Q2 2027
Cash and cash equivalents were $30.9 million at September 30, 2026, up from $18.563 million at December 31, 2025, and management expects funding into the second quarter of 2027.
-
Equity Raises Fund the Shortfall
Nine-month financing provided $42.322 million, including $28.623 million net from ATM programs and $13.582 million net from the July 2026 Offering, against $30.174 million of operating cash burn.
Analysis · ELTX · Life Sciences
The headline numbers look better — the quarterly loss fell to $7.979 million from $10.083 million a year ago and cash rose to $30.9 million from $18.563 million at year-end — but that improvement is bought with equity. Over nine months, roughly $42.3 million of financing flowed in, mostly $28.6 million of at-the-market sales and $13.6 million from the July 2026 offering, while operations burned $30.2 million. Management still states substantial doubt about the company's ability to continue as a going concern and puts runway only into the second quarter of 2027, which means another raise is likely within roughly two quarters. The share count has already climbed to 28.3 million from 17.8 million at December 31, 2025, so each new dollar of runway costs existing holders more of the company. As for the $2.2 million warrant fair-value gain that flattered other income, that is a non-cash mark-to-market, not cash generated.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ELTX was trading at $1.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $37.9M. The 52-week trading range was $1.40 to $16.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.